Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Interest & Investment Income (2017 - 2026)

Cogent Biosciences' Interest & Investment Income history spans 10 years, with the latest figure at $7.6 million for Q1 2026.

  • Quarterly Interest & Investment Income rose 157.72% to $7.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.3 million through Mar 2026, up 13.91% year-over-year, with the annual reading at $14.7 million for FY2025, 18.79% down from the prior year.
  • Interest & Investment Income came in at $7.6 million for Q1 2026, up from $5.5 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.6 million in Q1 2026 to a low of $107000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $3.9 million (2024), against an average of $3.4 million.
  • Year-over-year, Interest & Investment Income skyrocketed 2019.63% in 2023 and then plummeted 56.0% in 2025.
  • Cogent Biosciences' Interest & Investment Income stood at $2.1 million in 2022, then skyrocketed by 83.41% to $3.9 million in 2023, then fell by 0.28% to $3.9 million in 2024, then skyrocketed by 41.93% to $5.5 million in 2025, then surged by 38.91% to $7.6 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Interest & Investment Income are $7.6 million (Q1 2026), $5.5 million (Q4 2025), and $3.9 million (Q3 2025).